Breast Cancer MDx Platforms 162
TABLE 67 BREAST CANCER MDX TECHNOLOGY PLATFORMS 163
Breast Cancer Multivariate Diagnostic Tests 164
TABLE 68 COMMERCIAL LANDSCAPE FOR MULTIVARIATE BREAST CANCER TESTS, BY PARAMETER 164
TABLE 68 (CONTINUED) 165
Breast Cancer Multivariate … (Continued) 166
Regulatory Status of Gene Profiling Diagnostic Tests 167
TABLE 69 FDA REGULATORY POSITION ON IVDMIA 167
CERVICAL CANCER 168
TABLE 70 COMMERCIAL LANDSCAPE FOR HPV TESTS 168
TABLE 70 (CONTINUED) 169
COLORECTAL CANCER 170
Conventional Colorectal Cancer Screening Tests 170
TABLE 71 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER 171
Molecular Colorectal Cancer Diagnostics Tests 172
TABLE 72 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS 172
Molecular Colorectal Cancer … (Continued) 173
CUP 174
TABLE 73 COMMERCIAL MDX PLATFORMS FOR TISSUE OF ORIGIN TESTS 175
GASTRIC CANCER 176
LUNG CANCER 177
Lung Cancer (Continued) 178
OVARIAN CANCER 179
TABLE 74 OVARIAN CANCER SCREENING TESTS 179
TABLE 75 OVARIAN CANCER DIAGNOSTIC TEST STATUS 180
PANCREATIC CANCER 180
PEDIATRIC CANCERS 181
PROSTATE CANCER 181
Prostate Cancer (Continued) 182
COMPREHENSIVE CANCER TESTS 183
STATUS OF BIOCHIP-BASED INFECTIOUS DISEASE DIAGNOSTICS 183
SEPSIS 183
TUBERCULOSIS 184
MRSA 184
INFLUENZA 185
OTHER INFECTIOUS DISEASES 185
STATUS OF BIOCHIP-BASED DME DIAGNOSTICS 186
DMES 186
TABLE 76 MICROARRAY-BASED DME DIAGNOSTICS TESTS 186
DMEs (Continued) 187
WARFARIN DOSING 188
TABLE 77 WARFARIN CYP PGX DIAGNOSTICS TEST COMPETITOR SPACE 189
TABLE 77 (CONTINUED) 190
Warfarin Dosing (Continued) 191
'/>"/>
| SOURCE S OF COMPETITIVE ADVANTAGE IN DNA MICROARRAYS 265 Copyright©2010 PR Newswire. All rights reserved |